| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
CDK8 14 nM (Ki) GSK-3α 13 nM (Ki) GSK-3β 4 nM (Ki) PKCθ 109 nM (Ki)
|
|---|---|
| ln Vitro |
CDK8-IN-12 (compound 38) has a GI50 of 0.36 μM and specifically prevents MV4-11 acute myeloid leukemia cells from proliferating [1]. Significant reduction in STAT1 serine 727 phosphorylation is observed with CDK8-IN-12 (0.36, 0.72 μM; 2 hours) [1].
|
| ln Vivo |
The T1/2 of CDK8-IN-12 (Compound 38; intravenous administration; rat 5 mg/kg; mouse 2 mg/kg) in rats is 0.9 hours, while in mice it is 0.34 hours [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MV4-11 cells Tested Concentrations: 0.36, 0.72 μM Incubation Duration: 2 hrs (hours) Experimental Results: Dramatically decreased the phosphorylation of serine 727 on STAT1 at concentrations of their respective 1× GI50 values, but barely affected the level of total STAT1. |
| References |
| Molecular Formula |
C21H20CLN3O2
|
|---|---|
| Molecular Weight |
381.86
|
| Exact Mass |
381.12
|
| Elemental Analysis |
C, 66.05; H, 5.28; Cl, 9.28; N, 11.00; O, 8.38
|
| CAS # |
2613307-67-6
|
| PubChem CID |
162643699
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
27
|
| Complexity |
566
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1NCCC21CCN(C1=C(C=NC=C1C1OC3=CC=CC=C3C=1)Cl)CC2
|
| InChi Key |
ILMHDRGZABQLEW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20ClN3O2/c22-16-13-23-12-15(18-11-14-3-1-2-4-17(14)27-18)19(16)25-9-6-21(7-10-25)5-8-24-20(21)26/h1-4,11-13H,5-10H2,(H,24,26)
|
| Chemical Name |
8-(3-(benzofuran-2-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
|
| Synonyms |
CDK8-IN-12; CHEMBL4777349; BDBM50563322; CS-0636357
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~66.7 mg/mL (~174.6 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6188 mL | 13.0938 mL | 26.1876 mL | |
| 5 mM | 0.5238 mL | 2.6188 mL | 5.2375 mL | |
| 10 mM | 0.2619 mL | 1.3094 mL | 2.6188 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
